BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Retina, Laser capture microdissection, Rosiglitazone, rs7903146, DNMT1, Lung cancer)
Bookmark Forward

QuickView for lindau disease (phenotype)


Genetic Markers

Most Correlated Genes

Most Correlated SNPs

  1. CCND1
  2. VHL
  1. No SNPs found
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. REACTOME_OXYGEN_DEPENDENT_PROLINE_HYDROXYLATION_OF_HYPOXIA_INDUCIBLE_FACTOR_ALPHA
  2. PID_HIF1A_PATHWAY
  3. regulation of transcription from RNA polymerase II promoter in response to hypoxia
  4. BENPORATH_MYC_TARGETS_WITH_EBOX
  5. REACTOME_REGULATION_OF_HYPOXIA_INDUCIBLE_FACTOR_HIF_BY_OXYGEN
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. OMIM - Congenital disorder
  2. Mouse Phenotypes - Multisystem disorder
  3. Pancreatic islets from von Hippel Lindau KO mice and wildtypes
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Familial erythrocytosis 2 and von Hippel-Lindau disease in the same pediatric patient.
  2. The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis.
  3. Hemangioblastoma and von Hippel-Lindau Disease].
  4. Belzutifan: a novel therapy for von Hippel-Lindau disease.
  5. Re: Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau …
  2. Von Hippel-Lindau Disease Genetic Epidemiology Study
  3. Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
  4. Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
  5. PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
Explore Clinical Trials Results
  • Copyright © 2022 Illumina Inc. All rights reserved.